Bladder cancer drug combo shows promise in early trial
NCT ID NCT03324282
First seen May 22, 2026 · Last updated Jun 11, 2026 · Updated 3 times
Summary
This study tested whether adding the immunotherapy drug avelumab to standard chemotherapy (gemcitabine and cisplatin) could improve outcomes for people with advanced bladder cancer that had spread. The trial enrolled 65 patients and measured how many responded to treatment and how severe side effects were. The study was stopped early, but results help guide future research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de Besançon
Besançon, France
-
CHU de Bordeaux
Bordeaux, France
-
CHU de Poitiers
Poitiers, France
-
CHU de Strasbourg
Strasbourg, France
-
Centre François Baclesse
Caen, France
-
Centre Léon Bérard
Lyon, France
-
Hôpital Européen Georges-Pompidou, AP-HP
Paris, France
-
Hôpital Saint-Louis, AP-HP
Paris, France
-
Institut Bergonié
Bordeaux, France
-
Institut Gustave Roussy
Villejuif, France
-
Institut Paoli Calmettes
Marseille, France
-
Institut Universitaire du Cancer de Toulouse - Oncopole
Toulouse, France
-
Institut de cancérologie de l'Ouest - René Gauducheau
Nantes, France
Conditions
Explore the condition pages connected to this study.